AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

CRBU · NASDAQ · Biotechnology

Caribou Biosciences

Develops genome-edited allogeneic CAR-T candidates for blood cancers.

$1.65

After-hours close+0.04 (+2.17%)

At close$1.62(−2.71%)

Something off on this page? Send us feedback.

Profile

Caribou Biosciences, Inc.CRBUHealth Care

Develops off-the-shelf allogeneic CAR-T candidates for blood cancers using its chRDNA genome-editing platform. Its active pipeline centers on vispa-cel for B-cell non-Hodgkin lymphoma and CB-011 for multiple myeloma.

Uses its chRDNA CRISPR platform to engineer off-the-shelf, donor-derived allogeneic CAR-T therapies. The platform supports multiplex editing, including approaches intended to improve persistence or immune evasion, rather than individualized autologous treatment.

Active development is concentrated in vispa-cel, an anti-CD19 candidate for relapsed or refractory B-cell non-Hodgkin lymphoma, and CB-011, an anti-BCMA candidate for relapsed or refractory multiple myeloma. Neither candidate is approved, and the company has not commercialized a product or generated product-sales revenue. Its operating future depends on clinical development, regulatory interaction, manufacturing, funding, and development or commercialization revenue.

Company facts

CEORachel E. Haurwitz, Ph.D.

ListedJul 23, 2021

ExchangeNASDAQ

HeadquartersBerkeley, CA

CountryUnited States

Employees97

CIK0001619856

ISINUS1420381089

Key statistics

Market cap$160.7M

EPS (ttm)−$1.08

P/E (ttm)−1.50

ROE-89.1%

P/B1.67

P/S16.01

Dividend yield—

Beta2.33vs XLV 0.75

Year to date +1.6% · Average volume (30d) 1.1M

Analysts

Price target, next 12 months$5.00+208.6%Median of 9 analysts · vs the Aug 28 close

ConsensusBuy9 of 9 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $1.62

High$7.00+332.1%

Median$5.00+208.6%

Low$3.00+85.2%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Target
Nov 4, 2025	Truist Financial	Target	$7

Earnings

EPS

Estimate−$0.29

ReportedDue Nov 11, 2026

Revenue

Estimate$2.2M

ReportedDue Nov 11, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 13, 2026Q2 FY26	−$0.32	−$0.24	+25.9%	$2.3M	$1.5M	−34.2%	−1.86%
Aug 12, 2026Q2 FY26	−$0.32	−$0.24	+25.9%	$2.3M	$1.5M	−34.2%	−5.29%
May 7, 2026Q1 FY26	−$0.33	−$0.26	+21.2%	$2.2M	$2.4M	+8.3%	+3.19%
Mar 5, 2026Q4 FY25	−$0.33	−$0.28	+15.2%	$2.2M	$3.9M	+78.6%	+6.43%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$2.4M	$2.7M	$2.2M	$3.9M	$2.4M	$1.5M
Gross profit	$610.0K	$1.4M	−$20.2M	$3.9M	$1.7M	$1.5M
Operating income	−$42.9M	−$47.6M	−$29.4M	−$28.5M	−$26.3M	−$25.3M
Net income	−$40.0M	−$54.1M	−$27.5M	−$26.5M	−$25.1M	−$24.3M
Diluted EPS	−$0.43	−$0.58	−$0.30	−$0.28	−$0.26	−$0.24
Gross margin	25.9%	51.3%	-919.2%	100.0%	72.9%	100.0%
Operating margin	-1,823.8%	-1,784.0%	-1,337.6%	-722.0%	-1,096.4%	-1,690.4%

Fiscal years (4-quarter sums)FY21 $9.6M · FY22 $13.9M · FY23 $34.5M · FY24 $10.0M · FY25 $11.2M

Revenue by product · Q2 FY26

Reportable Segment$1.5M · 100%

Revenue by geography · Q2 FY26

United States$1.5M · 100%

Non-US$7.0K · 0%

Balance sheet, Jun 30, 2026Cash & short-term investments $112.3M · Total debt $26.7M · Total assets $142.8M · Shareholders' equity $98.1M

Dividends

No dividends on record.

Ownership

Institutions 49.66%49.25M sharesInsiders 4.66%4.62M sharesOther 45.68%45.31M shares

Shares outstanding 99.18M · Float 89.53M · 90.3% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
BlackRock, Inc.	7.18M	7.20%	13G	Jul 27, 2026
Vanguard Capital Management LLC	4.21M	4.24%	13F	Aug 13, 2026
Rachel E. Haurwitz · director, officer: President and CEO	3.82M	3.85%	Form 4	Feb 20, 2026
Geode Capital Management, LLC	2.37M	2.39%	13F	Aug 12, 2026
Two Sigma Investments, LP	1.05M	1.05%	13F	Aug 14, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Feb 25, 2026	Timothy P. Kelly	officer: Chief Technology Officer	−6,228	$1.93
Feb 24, 2026	Tina M. Albertson	officer: Chief Medical Officer	−1,066	$1.96
Feb 24, 2026	Ruhi Ahmad Khan	officer: Chief Business Officer	−6,938	$1.96
Feb 24, 2026	Barbara G. Mcclung	officer: Chief Legal Officer	−6,938	$1.96
Feb 24, 2026	Timothy P. Kelly	officer: Chief Technology Officer	−3,147	$1.96